Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17513917 | 1.00 | GHSR (0.46) | GHSR | |
| SCHEMBL19586388 | 1.00 | GHSR (0.46) | GHSR | |
| SCHEMBL29958798 | 1.00 | GHSR (0.46) | GHSR | |
| Relamorelin SCHEMBL19606783 | 0.93 | GHSR (0.54) | GHSR | |
| Relamorelin SCHEMBL19203687 | 0.93 | GHSR (0.54) | GHSR | |
| Relamorelin SCHEMBL19606784 | 0.93 | GHSR (0.54) | GHSR | |
| SCHEMBL18488500 | 0.86 | GHSR (0.57) | GHSR | |
| SCHEMBL20591195 | 0.86 | GHSR (0.54) | GHSR | |
| SCHEMBL18488501 | 0.84 | GHSR (0.54) | GHSR | |
| SCHEMBL19203560 | 0.81 | MEN1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330187-A1 | USE OF GHRELIN OR GHRELIN VARIANT FOR INCREASING DOSE INTENSITY OF CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH CANCER | OXEIA BIOPHARMACEUTICALS INC (US) | 2023-10-19 | — | — | US | claimed |
| WO-2022226116-A1 | GHRELIN TREATMENT OF BRAIN DYSFUNCTION DUE TO VIRAL INFECTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2022-10-27 | — | — | WO | claimed |
| US-12624290-B2 | Method for reducing white flicker | MERCK PATENT GMBH (DE) | 2026-05-12 | — | — | US | disclosed |
| US-12618008-B2 | Liquid crystal medium | MERCK PATENT GMBH (DE) | 2026-05-05 | — | — | US | disclosed |
| US-12618007-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2026-05-05 | — | — | US | disclosed |
| US-12612551-B2 | Liquid crystal medium | MERCK PATENT GMBH (DE) | 2026-04-28 | — | — | US | disclosed |
| US-12595417-B2 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2026-04-07 | — | — | US | disclosed |
| US-12559678-B2 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2026-02-24 | — | — | US | disclosed |
| US-12552991-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2026-02-17 | — | — | US | disclosed |
| US-12516245-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2026-01-06 | — | — | US | disclosed |
| US-20250387340-A1 | COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-12-25 | — | — | US | disclosed |
| US-20220127532-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | MERCK PATENT GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| US-11312909-B2 | Polymerizable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2022-04-26 | — | — | US | disclosed |
| US-20220119711-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2022-04-21 | — | — | US | disclosed |
| EP-3985085-A2 | LIQUID-CRYSTAL MEDIUM | Merck Patent GmbH (DE) | 2022-04-20 | — | — | EP | disclosed |
| US-20220112426-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2022-04-14 | — | — | US | disclosed |
| US-11299673-B2 | Liquid-crystal medium | MERCK PATENT GMBH (DE) | 2022-04-12 | — | — | US | disclosed |
| US-11299676-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2022-04-12 | — | — | US | disclosed |
| US-20220081617-A1 | LIQUID-CRYSTAL MEDIUM | MERCK PATENT GMBH (DE) | 2022-03-17 | — | — | US | disclosed |
| US-11274254-B2 | Compounds for the homeotropic alignment of liquid-crystalline media | MERCK PATENT GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127532-A1 | POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS | LPXN, VCL, LCP1 | GHSR 3576/4885 |
| US-12559678-B2 | Liquid-crystal medium | SCO2, CFD, CLCN2 | GHSR 1813/4885 |
| US-12552991-B2 | Liquid-crystalline medium | FES, VIM, INHA | GHSR 1301/4885 |
| US-12618007-B2 | Liquid-crystalline medium | SOST, NES, VIM | GHSR 273/4885 |
| US-12595417-B2 | Liquid-crystal medium | MEF2D, HCN2, HCN3 | GHSR 2702/4885 |
| US-12612551-B2 | Liquid crystal medium | FES, VIM, NES | GHSR 1147/4885 |
| US-11274254-B2 | Compounds for the homeotropic alignment of liquid-crystalline media | NEFM, MDN1, VCL | GHSR 606/4885 |
| US-11312909-B2 | Polymerizable compounds and the use thereof in liquid-crystal displays | VCL, LCP1, MAP1LC3C | GHSR 4021/4885 |
| US-12624290-B2 | Method for reducing white flicker | HCN4, HCN2, HCN3 | GHSR 4267/4885 |
| US-12618008-B2 | Liquid crystal medium | VIM, FES, NES | GHSR 1003/4885 |
| US-20250387340-A1 | COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | NPR1, NPPA, SLC7A1 | GHSR 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.